文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

血管紧张素-(1-7)输注用于ICU收治的COVID-19患者:无缝1-2期随机临床试验

Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial.
PubMed 文献 · Ann Intensive Care · 2024-09-04
一句话结论在ICU重症肺炎COVID-19患者中,持续静脉输注血管紧张素-(1-7) 10 mcg/Kg/天是安全的,但2期试验中无氧日数两组无显著差异。

这项由研究者发起的无缝1-2期随机临床试验,在2个ICU中检验了连续短期(最长7天)静脉输注血管紧张素-(1-7)在COVID-19患者中的安全性和有效性。1期开放标签试验中,剂量从5 mcg/Kg/天开始,24小时后增至10 mcg/Kg/天;2期双盲随机对照试验中,直接给予10 mcg/Kg/天,持续最长7天或至ICU出院。因招募率低研究提前终止,共纳入1期28例、2期79例患者,其中78例纳入意向治疗分析。2期主要终点无氧日数两组无显著差异(中位数19 [0-21] vs. 14 [0-18]天;p=0.15),但两期合并意向治疗分析显示治疗组无氧日数显著更高(19 [0-21] vs. 14 [0-18]天;绝对差-5天,95%CI [0-7],p=0.04)。

要点

  • 2期双盲随机对照试验中,血管紧张素-(1-7) 10 mcg/Kg/天组与对照组第28天无氧日数无显著差异(中位数19 [0-21] vs. 14 [0-18]天;p=0.15)。
  • 两期合并意向治疗分析中,治疗组无氧日数显著高于对照组(19 [0-21] vs. 14 [0-18]天;绝对差-5天,95%CI [0-7],p=0.04)。
  • 1期开放标签试验中,1例严重不良事件(心动过缓)被认为可能与输注相关,并因此停止输注。
  • 研究因招募率低提前终止,1期纳入28例、2期纳入79例,2期意向治疗分析78例,主要终点数据可用77例。
  • 作者结论认为,在ICU收治的重症肺炎COVID-19患者中,持续静脉输注血管紧张素-(1-7) 10 mcg/Kg/天是安全的。

适用人群与场景

  • ICU收治的COVID-19重症肺炎患者(1期28例,2期79例)。

处置流程与药物剂量

  • 1期开放标签试验:在标准治疗基础上,静脉输注血管紧张素-(1-7)从5 mcg/Kg/天开始,24小时后增至10 mcg/Kg/天。
  • 2期双盲随机对照试验:在标准治疗基础上,静脉输注血管紧张素-(1-7) 10 mcg/Kg/天,持续最长7天或至ICU出院。

红旗征与不能漏的情况

  • 1期出现1例严重不良事件(心动过缓),被认为可能与输注相关,因此停止输注。

研究设计与关键结果

  • 研究类型:由研究者发起的无缝1-2期随机临床试验,在2个ICU进行;2020年8月至2021年7月因招募率低提前终止。
  • 样本量:1期28例,2期79例;2期意向治疗分析78例,主要终点数据可用77例。
  • 1期主要终点:1例严重不良事件(心动过缓)被认为可能与输注相关,因此停止输注。
  • 2期主要终点:第28天无氧日数两组无显著差异(中位数19 [0-21] vs. 14 [0-18]天;p=0.15)。
  • 两期合并意向治疗分析:治疗组无氧日数显著高于对照组(19 [0-21] vs. 14 [0-18]天;绝对差-5天,95%CI [0-7],p=0.04)。

证据类型、等级与局限

  • 证据类型:无缝1-2期随机临床试验(1期开放标签,2期双盲随机对照)。
  • 局限:研究因招募率低提前终止。

对床旁实践的改变

  • 作者认为,在ICU收治的重症肺炎COVID-19患者中,持续静脉输注血管紧张素-(1-7) 10 mcg/Kg/天是安全的;2期意向治疗分析中无氧日数两组无显著差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The coronavirus-related disease (COVID-19) is mainly characterized by a respiratory involvement. The renin-angiotensin system (RAS) has a relevant role in the pathogenesis of COVID-19, as the virus enters host's cells via the angiotensin-converting enzyme 2 (ACE2).

METHODS: This investigator-initiated, seamless phase 1-2 randomized clinical trial was conceived to test the safety and efficacy of continuous short-term (up to 7 days) intravenous administration of Angiotensin-(1-7) in COVID-19 patients admitted to two intensive care units (ICU). In addition to standard of care, intravenous administration of Angiotensin-(1-7) was started at 5 mcg/Kg day and increased to 10 mcg/Kg day after 24 h (Phase 1; open label trial) or given at 10 mcg/Kg day and continued for a maximum of 7 days or until ICU discharge (Phase 2; double-blind randomized controlled trial). The rate of serious adverse events (SAEs) served as the primary outcome of the study for Phase 1, and the number of oxygen free days (OFDs) by day 28 for Phase 2.

RESULTS: Between August 2020 and July 2021, when the study was prematurely stopped due to low recruitment rate, 28 patients were included in Phase 1 and 79 patients in Phase 2. Of those, 78 were included in the intention to treat analysis, and the primary outcome was available for 77 patients. During Phase 1, one SAE (i.e., bradycardia) was considered possibly related to the infusion, justifying its discontinuation. In Phase 2, OFDs did not differ between groups (median 19 [0-21] vs. 14 [0-18] days; p = 0.15). When patients from both phases were analyzed in a pooled intention to treat approach (Phase 1-2 trial), OFDs were significantly higher in treated patients, when compared to controls (19 [0-21] vs. 14 [0-18] days; absolute difference -5 days, 95% CI [0-7] p = 0.04).

CONCLUSIONS: The main findings of our study indicate that continuous intravenous infusion of Angiotensin-(1-7) at 10 mcg/Kg day in COVID-19 patients admitted to the ICU with severe pneumonia is safe. In Phase II intention to treat analysis, there was no significant difference in OFD between groups. Trial Registration ClinicalTrials.gov Identifier: NCT04633772-Registro Brasileiro de Ensaios Clínicos, UTN number: U1111-1255-7167.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Martins ALV, Annoni F, da Silva FA, et al. Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial. Ann Intensive Care. 2024. PMID: 39231898. doi:10.1186/s13613-024-01369-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。